Remove 2026 Remove Insurance Remove Packaging
article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

Whether the results — and Immuneering’s approach — will hold up in a pivotal trial planned for 2026 remains to be seen. Editors pick stock via Getty Images GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down As more drugmakers aim for the lucrative weight loss market, patient challenges linger.

article thumbnail

BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals

Pharmaceutical Technology

BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory in space in 2026. Then, we will need to run pre-clinical trials of these crystals, which will be in 2026 or 2027. Image credit: Rini. com/ Shutterstock.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.

article thumbnail

Sanofi concludes Blueprint Medicines acquisition

Pharmaceutical Technology

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? It is expected to enhance gross margin and contribute positively to operating income and earnings per share after 2026. Give your business an edge with our leading industry insights.

article thumbnail

J&J seeks FDA approval for icotrokinra to treat psoriasis

Pharmaceutical Technology

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.

FDA 52
article thumbnail

Fangzhou and Novo Nordisk link on chronic disease management

Pharmaceutical Technology

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.

article thumbnail

Acumen and JCR partner on brain delivery therapy for Alzheimer’s

Pharmaceutical Technology

Anticipated next steps involve generating preclinical candidate data packages, which will include non-human primate studies expected in early 2026. How will RFK Jr’s American dream for vaccines play out? Following these outcomes, Acumen holds exclusive rights to develop up to two development candidates.